Clinical Research

Results from the Final Analysis of the Phase 3 iNNOVATE Study: Nursing Experience with Patients Receiving Ibrutinib plus Rituximab for Waldenström’s Macroglobulinemia
Kate Mimken, NP-C, Tolu Adewuya, MMedSci, PhD, CCRC, Bernhard Hauns, MD, PhD, Israel Arango-Hisijara, MD, Leonard T. Heffner, MD, Jeffrey V. Matous, MD
December 2021 Vol 12, No 12
The Clinical Utility of DCISionRT on Radiation Therapy Decision-Making in Patients with Ductal Carcinoma in Situ Following Breast-Conserving Surgery
Troy Bremer, PhD, Charles Cox, MD, Pat Whitworth, MD, Rakesh Patel, MD, Steve Shivers, PhD
December 2021 Vol 12, No 12
The Oncology Nurse’s Perspective on Recently Reported SOLAR-1 Findings
Jaimie Heldstab, FNP-BC, AOCNP, Janie A. Metsker, RN, BSN, CN-BN, ONN-CG
December 2021 Vol 12, No 12
Acalabrutinib vs Idelalisib plus Rituximab (IdR) or Bendamustine plus Rituximab (BR) in Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL): ASCEND Final Results
Paolo Ghia, MD, Andrzej Pluta, MD, Malgorzata Wach, MD, Daniel Lysak, MD, Tomas Kozak, MD, Martin Simkovic, MD, Polina Kaplan, MD, Iryna Kraychok, MD, Arpad Illes, MD, Javier de la Serna, MD, Sean Dolan, MD, Philip Campbell, MD, Gerardo Musuraca, MD, Abraham Jacob, MD, Eric J. Avery, MD, Jae Hoon Lee, MD, Denise Wang, Priti Patel, MD, Wojciech Jurczak, MD
November 2020 Vol 11, No 11
Acalabrutinib is a next-generation, highly selective, covalent Bruton tyrosine kinase inhibitor approved for patients with CLL, including those with R/R CLL.
Characteristics of Patients with a Complete Response Treated with Dabrafenib plus Trametinib Combination Therapy: Findings from Pooled COMBI-d and COMBI-v 5-Year Analysis
Caroline Robert, MD, PhD, Jean-Jacques Grob, Daniil Stroyakovskiy, Boguslawa Karaszewska, Axel Hauschild, MD, Evgeny Levchenko, Vanna Chiarion Sileni, MD, Jacob Schachter, MD, Claus Garbe, Igor Bondarenko, Paul Nathan, Antoni Ribas, Michael A. Davies, Keith Flaherty, Paul Burgess, Monique Tan, Eduard Gasal, MD, Dirk Schadendorf, MD, Georgina V. Long, MD, PhD
November 2020 Vol 11, No 11
Two large phase 3 studies (COMBI-d [NCT01584648] and COMBI-v [NCT01597908]) evaluated the efficacy and safety of oral dabrafenib 150 mg twice daily plus trametinib 2 mg once daily (D+T) as first-line therapy in patients (pts) with BRAF V600E- or V600K-mutant unresectable or metastatic cutaneous melanoma.
Characterization and Management of Adverse Reactions in Patients with Endometrial Carcinoma Receiving Lenvatinib plus Pembrolizumab (Study 111/KEYNOTE-146): Nurse Roles in Patient Education and Adverse-Reaction Management
Krysten Soldan, RN, Carolyn Johns, NP, Matthew H. Taylor, MD, Kathryn Gillis, PharmD, Robert Orlowski, MD, Min Ren, Vicky Makker
November 2020 Vol 11, No 11
Lenvatinib plus pembrolizumab demonstrated promising antitumor activity in endometrial carcinoma (EC) in a phase 1b/2 clinical trial (Study 111/KEYNOTE-146).
Impact of Late Dosing on Testosterone Suppression with Two Different Leuprolide Acetate Formulations: In Situ Gel and Microsphere – An Analysis of US Clinical Data
Tina DeNofrio, RN, BSN, OCN, Stuart N. Atkinson, MB, ChB, Deborah M. Boldt-Houle, PhD, Julia Vandross, NP-BC, BSN, MSN
November 2020 Vol 11, No 11
Luteinizing hormone-releasing hormone (LHRH) agonists are the most frequently used androgen deprivation therapy (ADT) for prostate cancer (PCa).
Improving Quality of Cancer Care by Integrating Considerations of Shared Importance to Patients and Family Caregivers into Clinical Pathway Platforms
Dena Schulman-Green, PhD, Emily Cherlin, PhD, MSW, Renee Capasso, BS, Sarah S. Mougalian, MD, Shiyi Wang, MD, PhD, Cary P. Gross, MD, Preeti S. Bajaj, PhD, Katherine Eakle, PharmD, Sharmi Patel, PharmD, Kerin Adelson, MD
November 2020 Vol 11, No 11
Clinical pathways have increasingly been incorporated into cancer care, aiming to encourage high-quality, evidence-based care while minimizing costs; however, clinical pathways infrequently incorporate patient and family perspectives, limiting patient-centeredness and value for shared decision-making.
Nursing Experience in Patients with Chronic Lymphocytic Leukemia Receiving First-Line Ibrutinib: Five Years of Follow-Up from the Phase 3 RESONATE-2 Study
Jillian Settlemire, RN, Edythe M. Greenberg, PhD, RN, FNP-BC, Indu Lal, MD, Carlos Amaya-Chanaga, MD, Jan A. Burger, MD, PhD, Steven Coutre, MD
November 2020 Vol 11, No 11
Ibrutinib is the only once-daily Bruton tyrosine kinase inhibitor that has shown significant progression-free survival (PFS) and overall survival (OS) benefits in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) across multiple randomized phase 3 studies.
Acalabrutinib vs Rituximab plus Idelalisib or Bendamustine by Investigator Choice in Relapsed/Refractory Chronic Lymphocytic Leukemia: Phase 3 ASCEND Study
Paolo Ghia, MD, Andrzej Pluta, MD, Malgorzata Wach, MD, Daniel Lysak, MD, Tomas Kozak, MD, Martin Simkovic, MD, Polina Kaplan, MD, Iryna Kraychok, MD, Arpad Illes, MD, Javier de la Serna, MD, Sean Dolan, MD, Philip Campbell, MD, Gerardo Musuraca, MD, Abraham Jacob, MD, Eric J. Avery, MD, Jae Hoon Lee, MD, Tianling Chen, MD, Wei Liang, PhD, Priti Patel, MD, Wojciech Jurczak, MD
November 2019 Vol 10, No 11
Acalabrutinib is a highly selective, potent, covalent Bruton tyrosine kinase inhibitor that has shown clinical benefit in patients with relapsed/refractory (RR) chronic lymphocytic leukemia (CLL).
Loading More Articles
Page 2 of 6
Results 11 - 20 of 60

Subscribe Today!

To sign up for our print publication or e-newsletter, please enter your contact information below.

I'd like to receive:

  • First Name *
    Last Name *
     
     
    Profession or Role
    Primary Specialty or Disease State
    Country
SUBSCRIBE

Contact Us | Editorial Board

© 2009- DBA AONN+ Academy of Oncology Nurse & Patient Navigators® PO Box 563, Cranbury, NJ 08512